Global Neuraminidase Inhibitors Drug Market Size, Status and Forecast 2024-2031

Report ID: 922427 | Published Date: Jan 2025 | No. of Page: 86 | Base Year: 2024 | Rating: 4.6 | Webstory: Check our Web story
Request Sample Report
Pre-Order Enquiry
Request Discount(%) 
1 Report Overview
    1.1 Study Scope
    1.2 Market Analysis by Type
        1.2.1 Global Neuraminidase Inhibitors Drug Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
        1.2.2 Oseltamivir
        1.2.3 Zanamivir
        1.2.4 Peramivir
        1.2.5 Laninamivir
    1.3 Market by Application
        1.3.1 Global Neuraminidase Inhibitors Drug Market Share by Application: 2016 VS 2021 VS 2027
        1.3.2 Hospital Pharmacy
        1.3.3 Retail Pharmacy
        1.3.4 Online Pharmacy
        1.3.5 Others
    1.4 Study Objectives
    1.5 Years Considered

2 Global Growth Trends
    2.1 Global Neuraminidase Inhibitors Drug Market Perspective (2016-2027)
    2.2 Neuraminidase Inhibitors Drug Growth Trends by Regions
        2.2.1 Neuraminidase Inhibitors Drug Market Size by Regions: 2016 VS 2021 VS 2027
        2.2.2 Neuraminidase Inhibitors Drug Historic Market Share by Regions (2016-2021)
        2.2.3 Neuraminidase Inhibitors Drug Forecasted Market Size by Regions (2022-2027)
    2.3 Neuraminidase Inhibitors Drug Industry Dynamic
        2.3.1 Neuraminidase Inhibitors Drug Market Trends
        2.3.2 Neuraminidase Inhibitors Drug Market Drivers
        2.3.3 Neuraminidase Inhibitors Drug Market Challenges
        2.3.4 Neuraminidase Inhibitors Drug Market Restraints

3 Competition Landscape by Key Players
    3.1 Global Top Neuraminidase Inhibitors Drug Players by Revenue
        3.1.1 Global Top Neuraminidase Inhibitors Drug Players by Revenue (2016-2021)
        3.1.2 Global Neuraminidase Inhibitors Drug Revenue Market Share by Players (2016-2021)
    3.2 Global Neuraminidase Inhibitors Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
    3.3 Players Covered: Ranking by Neuraminidase Inhibitors Drug Revenue
    3.4 Global Neuraminidase Inhibitors Drug Market Concentration Ratio
        3.4.1 Global Neuraminidase Inhibitors Drug Market Concentration Ratio (CR5 and HHI)
        3.4.2 Global Top 10 and Top 5 Companies by Neuraminidase Inhibitors Drug Revenue in 2020
    3.5 Neuraminidase Inhibitors Drug Key Players Head office and Area Served
    3.6 Key Players Neuraminidase Inhibitors Drug Product Solution and Service
    3.7 Date of Enter into Neuraminidase Inhibitors Drug Market
    3.8 Mergers & Acquisitions, Expansion Plans

4 Neuraminidase Inhibitors Drug Breakdown Data by Type
    4.1 Global Neuraminidase Inhibitors Drug Historic Market Size by Type (2016-2021)
    4.2 Global Neuraminidase Inhibitors Drug Forecasted Market Size by Type (2022-2027)

5 Neuraminidase Inhibitors Drug Breakdown Data by Application
    5.1 Global Neuraminidase Inhibitors Drug Historic Market Size by Application (2016-2021)
    5.2 Global Neuraminidase Inhibitors Drug Forecasted Market Size by Application (2022-2027)

6 North America
    6.1 North America Neuraminidase Inhibitors Drug Market Size (2016-2027)
    6.2 North America Neuraminidase Inhibitors Drug Market Size by Type
        6.2.1 North America Neuraminidase Inhibitors Drug Market Size by Type (2016-2021)
        6.2.2 North America Neuraminidase Inhibitors Drug Market Size by Type (2022-2027)
        6.2.3 North America Neuraminidase Inhibitors Drug Market Size by Type (2016-2027)
    6.3 North America Neuraminidase Inhibitors Drug Market Size by Application
        6.3.1 North America Neuraminidase Inhibitors Drug Market Size by Application (2016-2021)
        6.3.2 North America Neuraminidase Inhibitors Drug Market Size by Application (2022-2027)
        6.3.3 North America Neuraminidase Inhibitors Drug Market Size by Application (2016-2027)
    6.4 North America Neuraminidase Inhibitors Drug Market Size by Country
        6.4.1 North America Neuraminidase Inhibitors Drug Market Size by Country (2016-2021)
        6.4.2 North America Neuraminidase Inhibitors Drug Market Size by Country (2022-2027)
        6.4.3 United States
        6.4.4 Canada

7 Europe
    7.1 Europe Neuraminidase Inhibitors Drug Market Size (2016-2027)
    7.2 Europe Neuraminidase Inhibitors Drug Market Size by Type
        7.2.1 Europe Neuraminidase Inhibitors Drug Market Size by Type (2016-2021)
        7.2.2 Europe Neuraminidase Inhibitors Drug Market Size by Type (2022-2027)
        7.2.3 Europe Neuraminidase Inhibitors Drug Market Size by Type (2016-2027)
    7.3 Europe Neuraminidase Inhibitors Drug Market Size by Application
        7.3.1 Europe Neuraminidase Inhibitors Drug Market Size by Application (2016-2021)
        7.3.2 Europe Neuraminidase Inhibitors Drug Market Size by Application (2022-2027)
        7.3.3 Europe Neuraminidase Inhibitors Drug Market Size by Application (2016-2027)
    7.4 Europe Neuraminidase Inhibitors Drug Market Size by Country
        7.4.1 Europe Neuraminidase Inhibitors Drug Market Size by Country (2016-2021)
        7.4.2 Europe Neuraminidase Inhibitors Drug Market Size by Country (2022-2027)
        7.4.3 Germany
        7.4.4 France
        7.4.5 U.K.
        7.4.6 Italy
        7.4.7 Russia
        7.4.8 Nordic

8 Asia-Pacific
    8.1 Asia-Pacific Neuraminidase Inhibitors Drug Market Size (2016-2027)
    8.2 Asia-Pacific Neuraminidase Inhibitors Drug Market Size by Type
        8.2.1 Asia-Pacific Neuraminidase Inhibitors Drug Market Size by Type (2016-2021)
        8.2.2 Asia-Pacific Neuraminidase Inhibitors Drug Market Size by Type (2022-2027)
        8.2.3 Asia-Pacific Neuraminidase Inhibitors Drug Market Size by Type (2016-2027)
    8.3 Asia-Pacific Neuraminidase Inhibitors Drug Market Size by Application
        8.3.1 Asia-Pacific Neuraminidase Inhibitors Drug Market Size by Application (2016-2021)
        8.3.2 Asia-Pacific Neuraminidase Inhibitors Drug Market Size by Application (2022-2027)
        8.3.3 Asia-Pacific Neuraminidase Inhibitors Drug Market Size by Application (2016-2027)
    8.4 Asia-Pacific Neuraminidase Inhibitors Drug Market Size by Region
        8.4.1 Asia-Pacific Neuraminidase Inhibitors Drug Market Size by Region (2016-2021)
        8.4.2 Asia-Pacific Neuraminidase Inhibitors Drug Market Size by Region (2022-2027)
        8.4.3 China
        8.4.4 Japan
        8.4.5 South Korea
        8.4.6 Southeast Asia
        8.4.7 India
        8.4.8 Australia

9 Latin America
    9.1 Latin America Neuraminidase Inhibitors Drug Market Size (2016-2027)
    9.2 Latin America Neuraminidase Inhibitors Drug Market Size by Type
        9.2.1 Latin America Neuraminidase Inhibitors Drug Market Size by Type (2016-2021)
        9.2.2 Latin America Neuraminidase Inhibitors Drug Market Size by Type (2022-2027)
        9.2.3 Latin America Neuraminidase Inhibitors Drug Market Size by Type (2016-2027)
    9.3 Latin America Neuraminidase Inhibitors Drug Market Size by Application
        9.3.1 Latin America Neuraminidase Inhibitors Drug Market Size by Application (2016-2021)
        9.3.2 Latin America Neuraminidase Inhibitors Drug Market Size by Application (2022-2027)
        9.3.3 Latin America Neuraminidase Inhibitors Drug Market Size by Application (2016-2027)
    9.4 Latin America Neuraminidase Inhibitors Drug Market Size by Country
        9.4.1 Latin America Neuraminidase Inhibitors Drug Market Size by Country (2016-2021)
        9.4.2 Latin America Neuraminidase Inhibitors Drug Market Size by Country (2022-2027)
        9.4.3 Mexico
        9.4.4 Brazil

10 Middle East & Africa
    10.1 Middle East & Africa Neuraminidase Inhibitors Drug Market Size (2016-2027)
    10.2 Middle East & Africa Neuraminidase Inhibitors Drug Market Size by Type
        10.2.1 Middle East & Africa Neuraminidase Inhibitors Drug Market Size by Type (2016-2021)
        10.2.2 Middle East & Africa Neuraminidase Inhibitors Drug Market Size by Type (2022-2027)
        10.2.3 Middle East & Africa Neuraminidase Inhibitors Drug Market Size by Type (2016-2027)
    10.3 Middle East & Africa Neuraminidase Inhibitors Drug Market Size by Application
        10.3.1 Middle East & Africa Neuraminidase Inhibitors Drug Market Size by Application (2016-2021)
        10.3.2 Middle East & Africa Neuraminidase Inhibitors Drug Market Size by Application (2022-2027)
        10.3.3 Middle East & Africa Neuraminidase Inhibitors Drug Market Size by Application (2016-2027)
    10.4 Middle East & Africa Neuraminidase Inhibitors Drug Market Size by Country
        10.4.1 Middle East & Africa Neuraminidase Inhibitors Drug Market Size by Country (2016-2021)
        10.4.2 Middle East & Africa Neuraminidase Inhibitors Drug Market Size by Country (2022-2027)
        10.4.3 Turkey
        10.4.4 Saudi Arabia
        10.4.5 UAE

11 Key Players Profiles
    11.1 Roche
        11.1.1 Roche Company Details
        11.1.2 Roche Business Overview
        11.1.3 Roche Neuraminidase Inhibitors Drug Introduction
        11.1.4 Roche Revenue in Neuraminidase Inhibitors Drug Business (2016-2021)
        11.1.5 Roche Recent Development
    11.2 GSK
        11.2.1 GSK Company Details
        11.2.2 GSK Business Overview
        11.2.3 GSK Neuraminidase Inhibitors Drug Introduction
        11.2.4 GSK Revenue in Neuraminidase Inhibitors Drug Business (2016-2021)
        11.2.5 GSK Recent Development
    11.3 Gilead Sciences
        11.3.1 Gilead Sciences Company Details
        11.3.2 Gilead Sciences Business Overview
        11.3.3 Gilead Sciences Neuraminidase Inhibitors Drug Introduction
        11.3.4 Gilead Sciences Revenue in Neuraminidase Inhibitors Drug Business (2016-2021)
        11.3.5 Gilead Sciences Recent Development
    11.4 Daiichi Sankyo
        11.4.1 Daiichi Sankyo Company Details
        11.4.2 Daiichi Sankyo Business Overview
        11.4.3 Daiichi Sankyo Neuraminidase Inhibitors Drug Introduction
        11.4.4 Daiichi Sankyo Revenue in Neuraminidase Inhibitors Drug Business (2016-2021)
        11.4.5 Daiichi Sankyo Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix
    13.1 Research Methodology
        13.1.1 Methodology/Research Approach
        13.1.2 Data Source
    13.2 Disclaimer
    13.3 Author Details
List of Tables
    Table 1. Global Neuraminidase Inhibitors Drug Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
    Table 2. Key Players of Oseltamivir
    Table 3. Key Players of Zanamivir
    Table 4. Key Players of Peramivir
    Table 5. Key Players of Laninamivir
    Table 6. Global Neuraminidase Inhibitors Drug Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
    Table 7. Global Neuraminidase Inhibitors Drug Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
    Table 8. Global Neuraminidase Inhibitors Drug Market Size by Regions (2016-2021) & (US$ Million)
    Table 9. Global Neuraminidase Inhibitors Drug Market Share by Regions (2016-2021)
    Table 10. Global Neuraminidase Inhibitors Drug Forecasted Market Size by Regions (2022-2027) & (US$ Million)
    Table 11. Global Neuraminidase Inhibitors Drug Market Share by Regions (2022-2027)
    Table 12. Neuraminidase Inhibitors Drug Market Trends
    Table 13. Neuraminidase Inhibitors Drug Market Drivers
    Table 14. Neuraminidase Inhibitors Drug Market Challenges
    Table 15. Neuraminidase Inhibitors Drug Market Restraints
    Table 16. Global Neuraminidase Inhibitors Drug Revenue by Players (2016-2021) & (US$ Million)
    Table 17. Global Neuraminidase Inhibitors Drug Market Share by Players (2016-2021)
    Table 18. Global Top Neuraminidase Inhibitors Drug Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Neuraminidase Inhibitors Drug as of 2020)
    Table 19. Ranking of Global Top Neuraminidase Inhibitors Drug Companies by Revenue (US$ Million) in 2020
    Table 20. Global 5 Largest Players Market Share by Neuraminidase Inhibitors Drug Revenue (CR5 and HHI) & (2016-2021)
    Table 21. Key Players Headquarters and Area Served
    Table 22. Key Players Neuraminidase Inhibitors Drug Product Solution and Service
    Table 23. Date of Enter into Neuraminidase Inhibitors Drug Market
    Table 24. Mergers & Acquisitions, Expansion Plans
    Table 25. Global Neuraminidase Inhibitors Drug Market Size by Type (2016-2021) (US$ Million)
    Table 26. Global Neuraminidase Inhibitors Drug Revenue Market Share by Type (2016-2021)
    Table 27. Global Neuraminidase Inhibitors Drug Forecasted Market Size by Type (2022-2027) (US$ Million)
    Table 28. Global Neuraminidase Inhibitors Drug Revenue Market Share by Type (2022-2027) & (US$ Million)
    Table 29. Global Neuraminidase Inhibitors Drug Market Size Share by Application (2016-2021) & (US$ Million)
    Table 30. Global Neuraminidase Inhibitors Drug Revenue Market Share by Application (2016-2021)
    Table 31. Global Neuraminidase Inhibitors Drug Forecasted Market Size by Application (2022-2027) (US$ Million)
    Table 32. Global Neuraminidase Inhibitors Drug Revenue Market Share by Application (2022-2027) & (US$ Million)
    Table 33. North America Neuraminidase Inhibitors Drug Market Size by Type (2016-2021) (US$ Million)
    Table 34. North America Neuraminidase Inhibitors Drug Market Size by Type (2022-2027) & (US$ Million)
    Table 35. North America Neuraminidase Inhibitors Drug Market Size by Application (2016-2021) (US$ Million)
    Table 36. North America Neuraminidase Inhibitors Drug Market Size by Application (2022-2027) & (US$ Million)
    Table 37. North America Neuraminidase Inhibitors Drug Market Size by Country (2016-2021) & (US$ Million) 
    Table 38. North America Neuraminidase Inhibitors Drug Market Size by Country (2022-2027) & (US$ Million) 
    Table 39. Europe Neuraminidase Inhibitors Drug Market Size by Type (2016-2021) (US$ Million)
    Table 40. Europe Neuraminidase Inhibitors Drug Market Size by Type (2022-2027) & (US$ Million)
    Table 41. Europe Neuraminidase Inhibitors Drug Market Size by Application (2016-2021) (US$ Million)
    Table 42. Europe Neuraminidase Inhibitors Drug Market Size by Application (2022-2027) & (US$ Million)
    Table 43. Europe Neuraminidase Inhibitors Drug Market Size by Country (2016-2021) & (US$ Million) 
    Table 44. Europe Neuraminidase Inhibitors Drug Market Size by Country (2022-2027) & (US$ Million) 
    Table 45. Asia-Pacific Neuraminidase Inhibitors Drug Market Size by Type (2016-2021) (US$ Million)
    Table 46. Asia-Pacific Neuraminidase Inhibitors Drug Market Size by Type (2022-2027) & (US$ Million)
    Table 47. Asia-Pacific Neuraminidase Inhibitors Drug Market Size by Application (2016-2021) (US$ Million)
    Table 48. Asia-Pacific Neuraminidase Inhibitors Drug Market Size by Application (2022-2027) & (US$ Million)
    Table 49. Asia-Pacific Neuraminidase Inhibitors Drug Market Size by Region (2016-2021) & (US$ Million) 
    Table 50. Asia-Pacific Neuraminidase Inhibitors Drug Market Size by Region (2022-2027) & (US$ Million) 
    Table 51. Latin America Neuraminidase Inhibitors Drug Market Size by Type (2016-2021) (US$ Million)
    Table 52. Latin America Neuraminidase Inhibitors Drug Market Size by Type (2022-2027) & (US$ Million)
    Table 53. Latin America Neuraminidase Inhibitors Drug Market Size by Application (2016-2021) (US$ Million)
    Table 54. Latin America Neuraminidase Inhibitors Drug Market Size by Application (2022-2027) & (US$ Million)
    Table 55. Latin America Neuraminidase Inhibitors Drug Market Size by Country (2016-2021) & (US$ Million) 
    Table 56. Latin America Neuraminidase Inhibitors Drug Market Size by Country (2022-2027) & (US$ Million) 
    Table 57. Middle East & Africa Neuraminidase Inhibitors Drug Market Size by Type (2016-2021) (US$ Million)
    Table 58. Middle East & Africa Neuraminidase Inhibitors Drug Market Size by Type (2022-2027) & (US$ Million)
    Table 59. Middle East & Africa Neuraminidase Inhibitors Drug Market Size by Application (2016-2021) (US$ Million)
    Table 60. Middle East & Africa Neuraminidase Inhibitors Drug Market Size by Application (2022-2027) & (US$ Million)
    Table 61. Middle East & Africa Neuraminidase Inhibitors Drug Market Size by Country (2016-2021) & (US$ Million) 
    Table 62. Middle East & Africa Neuraminidase Inhibitors Drug Market Size by Country (2022-2027) & (US$ Million) 
    Table 63. Roche Company Details
    Table 64. Roche Business Overview
    Table 65. Roche Neuraminidase Inhibitors Drug Product
    Table 66. Roche Revenue in Neuraminidase Inhibitors Drug Business (2016-2021) & (US$ Million)
    Table 67. Roche Recent Development
    Table 68. GSK Company Details
    Table 69. GSK Business Overview
    Table 70. GSK Neuraminidase Inhibitors Drug Product
    Table 71. GSK Revenue in Neuraminidase Inhibitors Drug Business (2016-2021) & (US$ Million)
    Table 72. GSK Recent Development
    Table 73. Gilead Sciences Company Details
    Table 74. Gilead Sciences Business Overview
    Table 75. Gilead Sciences Neuraminidase Inhibitors Drug Product
    Table 76. Gilead Sciences Revenue in Neuraminidase Inhibitors Drug Business (2016-2021) & (US$ Million)
    Table 77. Gilead Sciences Recent Development
    Table 78. Daiichi Sankyo Company Details
    Table 79. Daiichi Sankyo Business Overview
    Table 80. Daiichi Sankyo Neuraminidase Inhibitors Drug Product
    Table 81. Daiichi Sankyo Revenue in Neuraminidase Inhibitors Drug Business (2016-2021) & (US$ Million)
    Table 82. Daiichi Sankyo Recent Development
    Table 83. Research Programs/Design for This Report
    Table 84. Key Data Information from Secondary Sources
    Table 85. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Neuraminidase Inhibitors Drug Market Share by Type: 2020 VS 2027
    Figure 2. Oseltamivir Features
    Figure 3. Zanamivir Features
    Figure 4. Peramivir Features
    Figure 5. Laninamivir Features
    Figure 6. Global Neuraminidase Inhibitors Drug Market Share by Application: 2020 VS 2027
    Figure 7. Hospital Pharmacy Case Studies
    Figure 8. Retail Pharmacy Case Studies
    Figure 9. Online Pharmacy Case Studies
    Figure 10. Others Case Studies
    Figure 11. Neuraminidase Inhibitors Drug Report Years Considered
    Figure 12. Global Neuraminidase Inhibitors Drug Market Size (US$ Million), Year-over-Year: 2016-2027
    Figure 13. Global Neuraminidase Inhibitors Drug Market Size (US$ Million), 2016 VS 2021 VS 2027
    Figure 14. Global Neuraminidase Inhibitors Drug Market Share by Regions: 2020 VS 2027
    Figure 15. Global Neuraminidase Inhibitors Drug Market Share by Regions (2022-2027)
    Figure 16. Global Neuraminidase Inhibitors Drug Market Share by Players in 2020
    Figure 17. Global Top Neuraminidase Inhibitors Drug Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Neuraminidase Inhibitors Drug as of 2020
    Figure 18. The Top 10 and 5 Players Market Share by Neuraminidase Inhibitors Drug Revenue in 2020
    Figure 19. Global Neuraminidase Inhibitors Drug Revenue Market Share by Type (2016-2021)
    Figure 20. Global Neuraminidase Inhibitors Drug Revenue Market Share by Type (2022-2027)
    Figure 21. North America Neuraminidase Inhibitors Drug Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 22. North America Neuraminidase Inhibitors Drug Market Share by Type (2016-2027)
    Figure 23. North America Neuraminidase Inhibitors Drug Market Share by Application (2016-2027)
    Figure 24. North America Neuraminidase Inhibitors Drug Market Share by Country (2016-2027)
    Figure 25. United States Neuraminidase Inhibitors Drug Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 26. Canada Neuraminidase Inhibitors Drug Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 27. Europe Neuraminidase Inhibitors Drug Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 28. Europe Neuraminidase Inhibitors Drug Market Share by Type (2016-2027)
    Figure 29. Europe Neuraminidase Inhibitors Drug Market Share by Application (2016-2027)
    Figure 30. Europe Neuraminidase Inhibitors Drug Market Share by Country (2016-2027)
    Figure 31. Germany Neuraminidase Inhibitors Drug Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 32. France Neuraminidase Inhibitors Drug Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 33. U.K. Neuraminidase Inhibitors Drug Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 34. Italy Neuraminidase Inhibitors Drug Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 35. Russia Neuraminidase Inhibitors Drug Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 36. Nordic Neuraminidase Inhibitors Drug Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 37. Asia-Pacific Neuraminidase Inhibitors Drug Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 38. Asia-Pacific Neuraminidase Inhibitors Drug Market Share by Type (2016-2027)
    Figure 39. Asia-Pacific Neuraminidase Inhibitors Drug Market Share by Application (2016-2027)
    Figure 40. Asia-Pacific Neuraminidase Inhibitors Drug Market Share by Region (2016-2027)
    Figure 41. China Neuraminidase Inhibitors Drug Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 42. Japan Neuraminidase Inhibitors Drug Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 43. South Korea Neuraminidase Inhibitors Drug Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 44. Southeast Asia Neuraminidase Inhibitors Drug Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 45. India Neuraminidase Inhibitors Drug Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 46. Australia Neuraminidase Inhibitors Drug Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 47. Latin America Neuraminidase Inhibitors Drug Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 48. Latin America Neuraminidase Inhibitors Drug Market Share by Type (2016-2027)
    Figure 49. Latin America Neuraminidase Inhibitors Drug Market Share by Application (2016-2027)
    Figure 50. Latin America Neuraminidase Inhibitors Drug Market Share by Country (2016-2027)
    Figure 51. Mexico Neuraminidase Inhibitors Drug Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 52. Brazil Neuraminidase Inhibitors Drug Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 53. Middle East & Africa Neuraminidase Inhibitors Drug Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 54. Middle East & Africa Neuraminidase Inhibitors Drug Market Share by Type (2016-2027)
    Figure 55. Middle East & Africa Neuraminidase Inhibitors Drug Market Share by Application (2016-2027)
    Figure 56. Middle East & Africa Neuraminidase Inhibitors Drug Market Share by Country (2016-2027)
    Figure 57. Turkey Neuraminidase Inhibitors Drug Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 58. Saudi Arabia Neuraminidase Inhibitors Drug Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 59. UAE Neuraminidase Inhibitors Drug Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 60. Roche Revenue Growth Rate in Neuraminidase Inhibitors Drug Business (2016-2021)
    Figure 61. GSK Revenue Growth Rate in Neuraminidase Inhibitors Drug Business (2016-2021)
    Figure 62. Gilead Sciences Revenue Growth Rate in Neuraminidase Inhibitors Drug Business (2016-2021)
    Figure 63. Daiichi Sankyo Revenue Growth Rate in Neuraminidase Inhibitors Drug Business (2016-2021)
    Figure 64. Bottom-up and Top-down Approaches for This Report
    Figure 65. Data Triangulation
    Figure 66. Key Executives Interviewed
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
Roche
GSK
Gilead Sciences
Daiichi Sankyo
Frequently Asked Questions
Neuraminidase Inhibitors Drug report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
Neuraminidase Inhibitors Drug report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
Neuraminidase Inhibitors Drug report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.

Related Reports

Anticholinergic Drug

Anticholinergic drugs are used to restrict the acetylcholine-provoked neurotransmission in differ ... Read More